BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Linvoseltamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Linvoseltamab\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06369467-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Linvoseltamab: Phase 1 readout est. (NCT06369467)
DESCRIPTION:Linvoseltamab\, phase 1.\nStudy: Short-Term Linvoseltamab Treat
 ment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunogl
 obulin E (IgE)-Mediated Food Allergy\nEstimated primary completion: 31 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoseltam
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6369467
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06376526-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06376526)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: IMMUNOPLANT
  for Newly Diagnosed Multiple Myeloma\nEstimated primary completion: 31 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoselta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06376526
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609940-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:Linvoseltamab: Phase 4 readout est. (NCT07609940)
DESCRIPTION:Linvoseltamab\, phase 4\, Multiple Myeloma.\nStudy: Adult Outpa
 tient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of C
 ytokine Release Syndrome (CRS)\nEstimated primary completion: 11 October 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076099
 40
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009899-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT07009899)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: BCMA Bispec
 ific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)\n
 Estimated primary completion: 1 February 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07009899
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Linvoseltamab: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Linvoseltamab\, phase 1\, Multiple Myeloma.\nStudy: A Study to 
 Examine the Effects of Novel Therapy Linvoseltamab in Combination With Oth
 er Cancer Treatments for Adult Participants With Multiple Myeloma That is 
 Resistant to Current Standard of Care Treatments\nEstimated primary comple
 tion: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 linvoseltamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05137054
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181941-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT07181941)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: Response-
 Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed\, Refra
 ctory\, or Triple-Class Relapsed/Refractory Multiple Myeloma\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07181941
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06292780-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280820
DTEND;VALUE=DATE:20280821
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT06292780)
DESCRIPTION:Linvoseltamab\, phase 1/2.\nStudy: A Trial to Learn if Linvosel
 tamab is Safe and Works in Adults With Relapsed or Refractory Systemic Lig
 ht Chain Amyloidosis (AL Amyloidosis)\nEstimated primary completion: 20 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoselta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06292780
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinat
 ion Therapy With Standard-of-Care Combination Regimens in Adult Participan
 ts With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary com
 pletion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /linvoseltamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07222761
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140524-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20320518
DTEND;VALUE=DATE:20320519
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06140524)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: A Proof-of-
 Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma
  Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk 
 Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smolde
 ring Multiple Myeloma\nEstimated primary completion: 18 May 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06140524
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06910124-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20321202
DTEND;VALUE=DATE:20321203
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT06910124)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: Linvoseltam
 ab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to 
 Deepen Responses or Redrive MRD Negativity After Relapse\nEstimated primar
 y completion: 2 December 2032. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06910124
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05955508-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330125
DTEND;VALUE=DATE:20330126
SUMMARY:Linvoseltamab: Phase 2 readout est. (NCT05955508)
DESCRIPTION:Linvoseltamab\, phase 2\, Multiple Myeloma.\nStudy: A Proof-of-
 Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult P
 articipants With Smoldering Multiple Myeloma at High Risk of Developing Mu
 ltiple Myeloma\nEstimated primary completion: 25 January 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05955508
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03761108-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330330
DTEND;VALUE=DATE:20330331
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT03761108)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: Phase 1/2
  Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Mult
 iple Myeloma\nEstimated primary completion: 30 March 2033. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03761108
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05730036-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330419
DTEND;VALUE=DATE:20330420
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT05730036)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Trial to 
 Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzum
 ab\, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/R
 efractory Multiple Myeloma\nEstimated primary completion: 19 April 2033. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05730036
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393282-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330727
DTEND;VALUE=DATE:20330728
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07393282)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Mu
 ltiple Myeloma (HR-SMM)\nEstimated primary completion: 27 July 2033. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/linvoseltamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07393282
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455851-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT07455851)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Trial t
 o Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Ad
 ult Participants With Relapsed/Refractory Multiple Myeloma\nEstimated prim
 ary completion: 30 September 2033. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07455851
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624513-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20331001
DTEND;VALUE=DATE:20331002
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07624513)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: D2 - Isa-Ib
 er-VD Induction\, Followed by Risk & Response Adapted Consolidation & Main
 tenance\, in Transplant-Eligible NDMM\nEstimated primary completion: 1 Oct
 ober 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/linvoselta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07624513
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669247-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20331111
DTEND;VALUE=DATE:20331112
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT06669247)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study t
 o Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination Wit
 h Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple My
 eloma\nEstimated primary completion: 11 November 2033. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06669247
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901725-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20350725
DTEND;VALUE=DATE:20350726
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT07901725)
DESCRIPTION:Linvoseltamab\, phase 3.\nStudy: Linvoseltamab Versus Daratumum
 ab\, Bortezomib\, Cyclophosphamide\, and Dexamethasone (Dara-Vcd) in Adult
  Participants With Newly Diagnosed Systemic Light Chain Amyloidosis\nEstim
 ated primary completion: 25 July 2035. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07901725
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05828511-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20351102
DTEND;VALUE=DATE:20351103
SUMMARY:Linvoseltamab: Phase 1/2 readout est. (NCT05828511)
DESCRIPTION:Linvoseltamab\, phase 1/2\, Multiple Myeloma.\nStudy: A Window 
 of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated\
 , and How Well it Works in Adult Participants With Recently Diagnosed Mult
 iple Myeloma Who Have Not Already Received Treatment\nEstimated primary co
 mpletion: 2 November 2035. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/linvoseltamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05828511
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-3159@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Linvoseltamab: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Linvoseltamab\, phase 3\, Multiple Myeloma.\nStudy: A Study to 
 Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treat
 ment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Tran
 splant\nEstimated primary completion: December 2036. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/linvoseltamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/linvoseltamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
